RT Journal Article
SR Electronic
T1 Rapid evaluation of neutralizing antibodies in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20185447
DO 10.1101/2020.09.01.20185447
A1 Zhang, Pingping
A1 Li, Baisheng
A1 Min, Wei
A1 Wang, Xiaohui
A1 Li, Zhencui
A1 Zhao, Yong
A1 Zhang, Huan
A1 Jiang, Min
A1 Zheng, Huanying
A1 Yang, Chao
A1 Zhang, Wei
A1 Zuo, Le
A1 Gao, Qi
A1 Yang, Zhengrong
A1 Li, Yanzhao
A1 Feng, Tiejian
A1 Lin, Changqing
A1 Hu, Qinghua
A1 Song, Tie
A1 Yang, Ruifu
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.09.01.20185447.abstract
AB The ongoing coronavirus disease 2019 (COVID-19) pandemic calls for a method to rapidly and conveniently evaluate neutralizing antibody (NAb) activity in patients. Here, an up-conversion phosphor technology-based point-of-care testing (UPT-POCT) and a microneutralization assay were employed to detect total antibodies against the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and NAb activity in COVID-19 patients’ sera, respectively, in order to determine if UPT-POCT could be used as a surrogate method for rapid evaluation of serum NAb activity in COVID-19 patients. In total, 519 serum samples from 213 recovered and 99 polymerase chain reaction re-positive (RP) COVID-19 patients were used in this report. We found that UPT-POCT reporting values correlated highly with NAb titers from 1:4 to 1:1024, with a correlation coefficient r = 0.9654 (P < 0.001), as well as protection rate against RP (r = 0.9886, P < 0.0001). As a significant point for reducing re-positive rate, UPT-POCT values of 4.380 ± 2.677, corresponding to NAb titer of 1:64, may be appropriate as an indicator for evaluating high efficiency of protection. This study demonstrates that the quantitative lateral flow based UPT-POCT, could be used to rapidly evaluate NAb titer, which is of importance for assessing vaccine immunization efficacy, herd immunity, and screening patient plasma for high NAbs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Beijing Municipal Science & Technology Program (Grant No. Z201100005420022), The National Key Research and Development Program of China (Grant No. 2018YFC1200502), National Natural Science Foundation of China (82041030), Sanming Project of Medicine in Shenzhen (No. SZSM201811071), The China National Science and Technology Major Projects Foundation (No. 2017ZX10303406), and Shenzhen Key Medical Discipline Construction Fund (No. SZXK064).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the ethics committees of Shenzhen Center for Disease Control and Prevention (QS2020060007).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.